RNA interference in ocular indications
First Claim
Patent Images
1. A method for delivering a nucleic acid to an eye of a subject in need thereof, comprisingadministering to the eye of the subject an sd-rxRNA®
- , in an effective amount to promote RNA interference by the sd-rxRNA®
in the eyewherein the sd-rxRNA®
comprises a guide strand and a passenger strand, wherein the sd-rxRNA®
includes a double stranded region and a single stranded region, wherein the double stranded region is from 8-15 nucleotides long, wherein the single stranded region is at the 3′
end of the guide strand and is 4-12 nucleotides long, wherein the single stranded region contains 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 phosphorothioate modifications, wherein at least 40% of the nucleotides of the isolated double stranded nucleic acid molecule are modified, wherein the sd-rxRNA has one end that is blunt, and wherein the sd-rxRNA is directed against a sequence comprising at least 12 contiguous nucleotides of a sequence selected from SEQ ID NOs;
1-182.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
340 Citations
14 Claims
-
1. A method for delivering a nucleic acid to an eye of a subject in need thereof, comprising
administering to the eye of the subject an sd-rxRNA® - , in an effective amount to promote RNA interference by the sd-rxRNA®
in the eyewherein the sd-rxRNA®
comprises a guide strand and a passenger strand, wherein the sd-rxRNA®
includes a double stranded region and a single stranded region, wherein the double stranded region is from 8-15 nucleotides long, wherein the single stranded region is at the 3′
end of the guide strand and is 4-12 nucleotides long, wherein the single stranded region contains 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 phosphorothioate modifications, wherein at least 40% of the nucleotides of the isolated double stranded nucleic acid molecule are modified, wherein the sd-rxRNA has one end that is blunt, and wherein the sd-rxRNA is directed against a sequence comprising at least 12 contiguous nucleotides of a sequence selected from SEQ ID NOs;
1-182. - View Dependent Claims (2, 3, 4, 5, 6, 7)
- , in an effective amount to promote RNA interference by the sd-rxRNA®
-
8. A method for delivering a nucleic acid to an eye of a subject in need thereof, comprising
administering to the eye of the subject an sd-rxRNA® - , in an effective amount to promote RNA interference by the sd-rxRNA®
in the eyewherein the sd-rxRNA®
comprises a guide strand and a passenger strand, wherein the sd-rxRNA®
includes a double stranded region and a single stranded region, wherein the double stranded region is from 8-15 nucleotides long, wherein the single stranded region is at the 3′
end of the guide strand and is 4-12 nucleotides long, wherein the single stranded region contains 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 phosphorothioate modifications, wherein at least 40% of the nucleotides of the isolated double stranded nucleic acid molecule are modified,wherein the sd-rxRNA is directed against a gene encoding CTGF and wherein the sense strand of the sd-rxRNA®
comprises at least 12 contiguous nucleotides of the sequence of SEQ ID NO;
967 (mU.mU. G.mC. A.mC.mC.mU.mU.mU.mC.mU*mA*mA.TEG-Chl), 969 (mU.mU. G.mC. A.mC.mC.mU.mU.mU.mC.mU*mA*mA.TEG-Chl), 949 (G.mC. A.mC.mC.mU.mU.mU.mC.mU. A*mG*mA.TEG-Chl), 1011 (G.mU. G. A.mC.mC. A. A. A. A. G*mU*mA.TEG-Chl), 1013 (G.mU. G. A.mC.mC. A. A. A. A. G*mU*mA.TEG-Chl), 1023 (G.mU. G. A.mC.mC. A. A. A. A. G*mU*mA.Teg-Chl), or 1025 (G.mU. G. A.mC.mC. A. A.mA. A. G*mU*mA.Teg-Chl) and/or wherein the antisense strand of the sd-rxRNA®
comprises at least 12 contiguous nucleotides of the sequence of SEQ ID NO;
968 (P.mU.fU. A. G. A.mA. A. G. G.fU. G.fC. A. A* A*fC* A*mA*mG* G.), 970 (P.mU.fU. A. G. A.mA. A. G. G.fU. G.fC.mA. A*mA*fC* A*mA*mG* G.), 950 (P.mU.fC.fU. A. G.mA. A.mA. G. G.fU. G.mC* A*mA* A*mC* A* U.), 1012 (P.mU. A.fC.fU.fU.fU.fU. G. G.fU.mC. A.mC* A*mC*mU*mC*mU* C.), 1014 (P.mU. A.fC.fU.fU.fU.fU. G. G.fU.fC. A.mC* A*fC*mU*fC*mU* C.), 1024 (P.mU. A.fC.fU.fU.fU.fU. G. G.fU.fC. A.mC* A*fC*mU*fC*mU* C.), or 1026 (P.mU. A.fC.fU.fU.fU.fU. G. G.fU.mC. A.mC* A*mC*mU*mC*mU* C.). - View Dependent Claims (9, 10, 11, 12, 13, 14)
- , in an effective amount to promote RNA interference by the sd-rxRNA®
Specification